NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
NorthSea Therapeutics Announces Positive Phase 2 Topline Data in First-ever Randomized Placebo-controlled Study of an Oral Therapy in Intestinal Failure-Associated Liver Disease<
09 Nov 2026

NorthSea Therapeutics Announces Positive Phase 2 Topline Data in First-ever Randomized Placebo-controlled Study of an Oral Therapy in Intestinal Failure-Associated Liver Disease

Orziloben-treated patients saw rapid and sustained improvements in cholestatic liver injury.
CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD<
22 Oct 2026

CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD

First clinical evidence on adaptive support with the CorWave LVAS
Ambrose Healthcare Acquires AM-Pharma for up to €161 million, Expanding its Rare Disease Pipeline and Gaining a European Base<
20 Oct 2026

Ambrose Healthcare Acquires AM-Pharma for up to €161 million, Expanding its Rare Disease Pipeline and Gaining a European Base

HPP is a rare, inherited chronic disease caused by low alkaline phosphatase activity
European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease<
28 Sep 2026

European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Approval is based on NEXUS data and follows positive CHMP opinion in July; first European launch is expected by end of 2026
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer<
24 Sep 2026

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

More than half of the patients planned for the clinical study have already been enrolled,

Anaconda Biomed Secures $56 Million Financing from New and Existing Investors<
23 Sep 2026

Anaconda Biomed Secures $56 Million Financing from New and Existing Investors

Clinical Evidence Shows High Reperfusion and First Pass Success Rates with the Device
Ysios Capital 2025 / H1 2026 Review<
28 Jul 2026

Ysios Capital 2025 / H1 2026 Review

Over the past eighteen months, we have combined strong portfolio execution with the expansion of our investment platform.
Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch<
28 Jul 2026

Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch

Builds on the €50m secured in 2025 and supports Xeltis’ next phase of clinical, regulatory and commercial execution
NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease<
24 Jul 2026

NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease

Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline<
22 Jul 2026

Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.